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Global Analysis of DNA Methylation Variation
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Associated Variants in Distal Regulatory Elements
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Alicja Wilk,1 Amy Barrett,6 Kerrin S. Small,2 Bing Ge,5 Maxime Caron,5 So-Youn Shin,1 the Multiple
Tissue Human Expression Resource Consortium, Mark Lathrop,5 Emmanouil T. Dermitzakis,4
Mark I. McCarthy,3,6,7 Timothy D. Spector,2 Jordana T. Bell,2 and Panos Deloukas1,10,*
Epigenetic modifications such as DNAmethylation play a key role in gene regulation and disease susceptibility. However, little is known
about the genome-wide frequency, localization, and function of methylation variation and how it is regulated by genetic and environ-
mental factors.We utilized theMultiple TissueHuman Expression Resource (MuTHER) and generated Illumina 450K adiposemethylome
data from 648 twins. We found that individual CpGs had low variance and that variability was suppressed in promoters. We noted that
DNA methylation variation was highly heritable (h2median ¼ 0.34) and that shared environmental effects correlated with metabolic
phenotype-associated CpGs. Analysis of methylation quantitative-trait loci (metQTL) revealed that 28% of CpGs were associated
with nearby SNPs, and when overlapping them with adipose expression quantitative-trait loci (eQTL) from the same individuals, we
found that 6% of the loci played a role in regulating both gene expression and DNAmethylation. These associations were bidirectional,
but there were pronounced negative associations for promoter CpGs. Integration of metQTL with adipose reference epigenomes and
disease associations revealed significant enrichment of metQTL overlapping metabolic-trait or disease loci in enhancers (the strongest
effects were for high-density lipoprotein cholesterol and body mass index [BMI]). We followed up with the BMI SNP rs713586, a
cg01884057 metQTL that overlaps an enhancer upstream of ADCY3, and used bisulphite sequencing to refine this region. Our results
showed widespread population invariability yet sequence dependence on adipose DNAmethylation but that incorporating maps of reg-
ulatory elements aid in linking CpG variation to gene regulation and disease risk in a tissue-dependent manner.Introduction
Themolecular basis of complex traits and diseases has only
partially been explained by common sequence variants.1
Of the hundreds of already identified common complex-
trait-associated genetic loci, the majority of which map
to noncoding DNA,2 only a few have been translated to
biological mechanisms. An approach to understanding
noncoding variation and its impact on quantitative traits
and disease susceptibility is linking cellular phenotypes,
such as gene expression3–5 or chromatin state6,7 in dis-
ease-targeted cells or tissues, with common sequence vari-
ants.
Epigenetic variation such as DNA methylation is now
acknowledged to make a significant contribution to com-
plex disease susceptibility.8,9 To this end, we have devel-
oped one of the largest population collections of multiple
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project, where the tissues were obtained through punch bi-
opsies from an area adjacent and inferior to the umbilicus.
Using this resource, we recently presented the most precise
decomposition to date of gene expression variability: that
genetic effects contribute on average ~30% of the variation
in gene expression. We also showed evidence of the impor-
tance of using disease-targeted tissue or cell panels for ac-
curate interpretation of functionality of disease loci from
genome-wide association studies (GWASs).10 We are now
expanding our efforts on population-based cellular pheno-
typing to also include methylome data.
DNA methylation patterns differ with age;11 compared
with newborns, centenarians have more hypomethylated
CpGs,12 believed to be regulated by stochastic, environ-
mental, and genetic variation.13 For instance, several
studies are reporting direct effects of cigarette smoking
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correlation between epigenetic modification and common
diseases.8 A pioneering study using allele-specific DNA
methylation and mRNA expression showed evidence of a
genotype-dependent effect of DNA methylation, as well
as a correlation with gene expression.16 It was also demon-
strated that the sequence variants regulating DNA methyl-
ation are predominantly located in cis. These results have
been confirmed and followed up in more detail in more
recent studies exploring the effect of genetic factors
in modulating DNA methylation,17–19 providing further
evidence of both a strong genetic component in interindi-
vidual DNA methylation variation and a common mecha-
nism regulating gene expression and DNA methylation.
However, most of the studies presented to date have
been limited to either whole-blood-derived DNA samples
or targeted arrays of promoter regions (i.e., Illumina
27K), which include only a small fraction of methylation
variation. Although several studies have demonstrated
that changes in promoter methylation could significantly
affect gene expression,20,21 the function of DNA methyl-
ation in intergenic and gene-body regions is less defined.
Consequently, studies using more homogeneous cell or
tissue samples for the analysis of genome-wide DNA
methylation patterns in larger sample sizes are in high de-
mand.
Weestimatedmethylation levels of 485,764 sites covering
not only gene promoters but also several other genomic fea-
tures22 in subcutaneous adipose tissue derived from 648
female twins. Taking advantage of the twin structure, we
performed large-scale heritability analysis of global DNA
methylationvariationbydissecting it into genetic and envi-
ronmental (both common and unique) effects. In addition,
we used previously collected genomic (SNP) and transcrip-
tomic (IlluminaHT12) data to assess the impact of common
variants on DNA methylation differences and to estimate
the global correlation with expression of nearby genes.
Finally, in an attempt to understand the functional role of
epigenetic variants, we correlated our methylation quanti-
tative-trait loci (metQTL) findings with publicly available
reference epigenome data on human cells differentiated
into adipocytes from the National Institutes of Health
(NIH) RoadMap Epigenomics Project.23 The complete anal-
ysis outline is presented in Figure S1, available online.Subjects and Methods
Sample Inclusion
A total of 662 adipose tissue samples collected in the MuTHER
study were included herein. The MuTHER study includes 856
female European-descent individuals recruited from the TwinsUK
Adult Twin Registry,24 as previously described.10 In brief, 8 mm
punch biopsies were taken from a relatively photo-protected area
adjacent and inferior to the umbilicus. Subcutaneous adipose tis-
sue was carefully dissected from each biopsy, weighted and split
into multiple pieces, and immediately stored in liquid nitrogen
until analysis. All the procedures followed were in accordance
with the ethical standards of the St. Thomas’ Research Ethics Com-The Americanmittee (REC reference 07/H0802/84) at St. Thomas’ Hospital in
London, and all study subjects provided written informed con-
sent. As recently described, RNA was extracted from the MuTHER
adipose tissues and used for expression profiling using Illumina
Human HT-12 V3 BeadChips.DNA Isolation and Bisulphite Conversion
In order to avoid sampling biases, we randomized the included ad-
ipose tissue samples prior to DNA extraction. Genomic DNA was
then isolated with a NORGEN DNA Purification Kit (Norgen Bio-
tek Corporation) according to the manufacturer’s protocol and
quantified with PicoGreen. Prior to bisulphite conversion, the
DNA samples were further randomized, and exactly 700 ng of
each DNA sample was taken for bisulphite conversion with the
EZ-96 DNAMethylation Kit (Zymo Research) according to the sup-
plier’s protocol. Before proceeding with methylation profiling, we
quantified concentrations of the bisulphite-treated DNA samples
with NanoDrop ND-1000 (NanoDrop Technologies).Genome-wide Methylation Profiling
Methylation profiling was performed on the bisulphite-converted
samples with the Illumina Infinium HumanMethylation450
BeadChip; 5 ml of each eluted bisulphite-treated DNA sample was
processed according to the protocol supplied by Illumina. The
methylation array targeted 485,764 methylation sites across the
genome with both the Infinium I (two bead types per CpG site;
one each for the methylated and unmethylated states) and II (one
bead type per CpG site; the methylated state is determined at the
single-base extension step) assay designs. Given the complexity
of the probe design,methylation scores (beta values) have different
distributions for the different probe types (Figure S2). The Bead-
Chips were scanned with the IlluminaHiScan SQ scanner, and
raw data were imported to the GenomeStudio v.2010.3 software
with the methylation module 1.8.2 for the extraction of the image
intensities. Sample quality control based on probe detection and
using theGenomeStudiop values of detectionof signal above back-
ground resulted in the exclusion of 11 samples (at least 95%
coverage per sample was required). In addition, probes that failed
in at least one individual (n ¼ 13,686) and that were not reported
by the GenomeStudio software were discarded.
The signal intensities for the methylated and unmethylated
states were then quantile normalized for each probe type sepa-
rately, and beta values were calculated with R 2.12.0.25 Beta values
are the ratio of the normalized intensity of the methylated bead
type to the combined normalized locus intensity, and they range
from 0 (hypomethylated) to 1 (hypermethylated). Principal-
component analysis of the beta values was then performed for as-
sessing the impact of known technical factors on the variation in
beta values, as well as for detecting any potential outliers. Bead-
chip, bisulphite-sequencing (BS) conversion efficiency (assessed
with the built-in BS conversion efficiency controls), and BS-treated
DNA input were shown to contribute significantly to the variation
in beta levels and were thus included together with age as covari-
ates in subsequent analysis. After principal-component analysis,
three samples were considered outliers and removed, leaving a to-
tal of 648 samples for subsequent analysis (see below).Probe Mapping and Annotation
To test for cross hybridization, we mapped all probe sequences
of Illumina’s Infinium HumanMethylation450K BeadChip (n ¼
485,764) to the human reference genome (GRCh37) with BLATJournal of Human Genetics 93, 876–890, November 7, 2013 877
with default parameters.26 As described earlier, probes that were
mapped to multiple locations with at least two mismatches were
considered to be ambiguous.18 A total of 459,433 uniquely
mapped autosomal probes were chosen and further filtered for
sequence polymorphisms. Sequence variants from CEU (Utah res-
idents with ancestry from northern and western Europe from the
CEPH collection) populations were downloaded from the 1000
Genomes Project (release 3).27 Irrespective of their frequency,
SNPs spanning the ten bases around the methylated base of the
probes were deleted. A threshold of minor allele frequency
(MAF) ¼ 1% was set for SNPs overlapping the rest of the probe
sequence. In addition, probes overlapping copy-number variants
were deleted. This resulted in a final set of 357,802 probes. How-
ever, we restricted all of our analysis to 344,303 sites that were
measured across all samples (Table S1).
Filtered probes were assigned to CpG islands (CGIs) and RefSeq
transcripts that were downloaded from the UCSC Genome
Browser. With the methylated site as a reference, all the probes
were allocated to different gene properties, namely TSS200 (200
bases away from the 50 end of the transcription start site [TSS]),
TSS1500 (1,300 bases away from the 50 end of TSS200), the 50
UTR, the first exon, the gene body, and the 30 UTR. Probes that
were 2 kb away from either side of the CGIs were considered to
be shores, and shelves were a further 2 kb away from either side
of the shores.22Methylation and Gene Expression Association
Associations between DNA methylation and gene expression
levels were analyzed for 210,984 methylation and 18,818 expres-
sion probes situated on or 1,500 bp upstream of 13,532 genes.
To test the associations, we used a linear mixed-effects model in
R25 with the lme4 package28 lmer() function, fitted by maximum
likelihood. The linear mixed-effects model was adjusted for both
fixed effects (age, beadchip, BS conversion efficiency, and BS-
treated DNA input) and random effects (family relationship and
zygosity). We used a likelihood ratio test to assess the significance
of the gene expression effect. The p value of the gene expression
effect in each model was calculated from the Chi-square distribu-
tion with 1 degree of freedom (df) and 2log(likelihood ratio) as
the test statistic. False-discovery rate (FDR) was calculated with
the q value package29 implemented in R 2.11.25Heritability Analysis
The classical twin design was applied for comparing the similarity
of monozygotic (MZ) and dizygotic (DZ) twins by means of the
ACE model, which partitions the variance into additive genetic
(A), common environment (variance due to environmental effects
shared within twin pairs) (C), and unique environment (environ-
mental effects not shared within twin pairs) (E). Because all twin
pairs included in the study visited the clinic in pairs and because
MZ twins share 100% of their genes, any differences arising be-
tween them in these circumstances are unique (E). The correlation
observed betweenMZ twins thus provides an estimate of AþC. In
contrast, DZ twins have a common shared environment but share
on average only 50% of their genes, such that the correlation be-
tween DZ twins is a direct estimate of 0.5(A þ C). Consequently,
twice the difference between MZ and DZ twins gives the genetic
additive effect (A), and the common environment (E) is the MZ
correlationminus the estimate of the genetic effect (A). A standard
linear mixedmodel was used for estimating these variance compo-
nents, as previously described.30 All available complete twin pairs878 The American Journal of Human Genetics 93, 876–890, Novembwere included in the model and corresponded to 97 MZ and 162
DZ pairs. Age, beadchip, BS conversion efficiency, and BS-treated
DNA input were included in the model as covariates.
Pathway Analysis
In order to visualize the data in the context of biological networks,
we analyzed functions or pathways data through the use of the In-
genuity Pathway Analysis (IPA) system (Ingenuity Systems). The
data set containing genes for which shared environmental effect
accounted for more than 30% of the total variance in methylation
levels was uploaded to the application. Each gene identifier was
mapped to its corresponding gene object in the Ingenuity Knowl-
edge Base. These genes, called focus genes, were overlaid onto a
global molecular network developed from information contained
in the Ingenuity Knowledge Base. The functional analysis identi-
fied the biological functions that were most significant to the
data set. In the data set, genes that met the cutoff and were asso-
ciated with biological functions in the Ingenuity Knowledge
Base were considered for the analysis. Fisher’s exact test was used
for calculating a p value determining the probability that each bio-
logical function assigned to the data set was due to chance alone.
Insulin Association
Associations between DNA methylation and insulin levels were
modeled with a linear mixed-effects model in R25 with the lme4
package28 lmer() function, fitted by maximum likelihood. The
linear mixed-effects model was adjusted for both fixed effects
(age, beadchip, BS conversion efficiency, and BS-treated DNA
input) and random effects (family relationship and zygosity). A
likelihood ratio test was used for assessing the significance of the
phenotype effect. The p value of the phenotype effect in each
model was calculated from the Chi-square distribution with 1 df
and 2log(likelihood ratio) as the test statistic. Fisher’s exact test
was used for assessing enrichment of phenotype associations in
the set of shared environmentally controlled sites versus the full
set of methylation sites.
Genotyping and Genotype Imputation
Genotyping of the TwinsUK data set (n ¼ ~6,000) was done with a
combination of Illumina arrays (HumanHap300, Human-
Hap610Q, 1M-Duo, and 1.2MDuo 1M). Intensity data for each
of the three arrays were pooled separately (with 1M-Duo and
1.2MDuo 1M pooled together), and genotypes were called with
the Illuminus31 calling algorithm with the use of a threshold
on a maximum posterior probability of 0.95, as previously
described.32
Imputation was performed with the IMPUTE software package
(v.2)33 with two reference panels, P0 (HapMap2, rel 22, combined
CEU, YRI [Yoruba in Ibadan, Nigeria], and ASN [East Asian] panels)
and P1 (610kþ, including the combined HumanHap610k and 1M
array). After imputation, SNPs were filtered at a MAF > 5% and
IMPUTE info value of >0.8.
metQTL Analysis
Associations between DNA methylation levels and probabilities
of imputed genotypes (MAF > 5%, info > 0.8) were tested in
samples of related individuals by means of a two-step statistical
approach implemented in the GenABEL and ProbABEL pack-
ages.34,35 In brief, a linear mixed (polygenic) model of methyl-
ation levels, covariates, and a kinship matrix was estimated in
GenABEL, and a score test in ProbABEL followed. Age, beadchip,er 7, 2013
BS conversion efficiency, and BS-treated DNA input were
included as cofactors. In total, 603 adipose samples had both
methylation profiles and imputed genotypes and were thus
included in the analysis. Cis analysis was limited to SNPs located
within 100 kb of either side of the probe location. FDR for the cis
analysis was calculated with the q value package29 implemented
in R 2.11.25
The score test is known to slightly underestimate the additive
effect sizes36 of each SNP, so the top association per probe was
validated with a linear mixed-effects model in R with the lme4
package28 lmer() function, fitted by maximum likelihood. The
linear mixed-effects model was adjusted for both fixed effects
(age, beadchip, BS conversion efficiency, and BS-treated DNA
input) and random effects (family relationship and zygosity). A
likelihood ratio test was then applied for assessing the significance
of the SNP effect. The p value of the SNP effect in each model was
calculated from the Chi-square distribution with 1 df and
2log(likelihood ratio) as the test statistic.
To estimate the significance of our calculated FDR levels, we per-
formed permutation tests as follows: 100 probes were selected at
random from probes with at least one SNP association at a 1%
FDR. For each probe, models were fitted to all SNPs in its 100 kb
cis region. Current results are based on 100 permutations of the
genotype data; the same permutation scheme (accounting for
relatedness) was applied across the whole 100 kb cis region for pre-
serving linkage disequilibrium (LD) structure. We then calculated
the percentage of models in each permutation round (across all
probe-SNP models) with a parametric p value below the threshold
corresponding to a 1% FDR estimated from the data with a q value.
We found ~0.46% of the ‘‘permuted models’’ to have a p < 2.7 3
103 (corresponding to a 1% FDR) by chance. However, at the
1% FDR threshold, we found that in 2/100 permutation rounds,
at least 1% of 14,803 random models had a p value below the
threshold purely by chance. From the permuted data, we thus esti-
mated that p< 6.463 103 corresponded to a 1% FDR, suggesting
that the q value slightly overestimated the significance required at
the selected FDR level when data were correlated.metQTL and eQTL Overlap
Expression profiling of the MuTHER twins was performed on Illu-
mina HT12 BeadChip as previously described.10 A total of 3,478
cis-eQTL (defined as a 1 Mb region on either side of the transcript)
at a 1% FDR using 2,029,988 imputed SNPs (MAF > 5% and
IMPUTE info value > 0.8) were discovered.10
To test the overlap of SNPs associated with methylation and
expression, we used a two-step procedure. First, we considered
expression and methylation probes situated on the same gene or
1,500 bp upstream of the gene (applicable to methylation probes
only) and asked whether the top SNP associated with expression is
the same as that associated with DNA methylation. In the second
step, we used conditional analysis to test whether top SNPs asso-
ciated with expression probes are in LD with any of the significant
SNPs associated with methylation probes.37 For this, we ran a
linear mixed model by conditioning on top SNPs associated
with corresponding expression probes (expression score was
used as the response variable, and batch and age were used as co-
variates).Analysis of ChIP-Seq Data
Aligned chromatin immunoprecipitation sequencing (ChIP-seq)
reads (.BAM files) from nuclei from adipose tissue derived fromThe Americanfive independent donors were downloaded from the NIH Road-
map Epigenomics Project from the Gene Expression Omnibus
repository. More specifically, aligned ChIP-seq reads of the
H3K4me1 and H3K4me3 marks and the ChIP-seq input were
used. The corresponding accession numbers were GSM621425,
GSM669908, GSM669975, GSM670045, and GSM772757 for
H3K4me1; GSM621435, GSM669925, GSM669988, GSM669998,
and GSM670041 for H3K4me3; and GSM621401, GSM669934,
GSM669940, GSM669984, and GSM670043 for the ChIP-seq
input files. The embargo end date spanned from August 12,
2011 to September 28, 2012. The ChIP-seq data were processed
as recently described.38 In brief, each file of the H3K4me1 and
H3K4me3 marks was divided into 100 bp bins, and the number
of reads within each bin was counted. For generating normalized
intensity signals, the counts in each bin were further normalized
according to the total number of reads. Input reads were processed
in the same way, and their normalized signal-intensity values were
subsequently subtracted from the ChIP-seq bins. The H3K4me1
and H3K4me3 bins were then ranked according to their normal-
ized signal-intensity values, and the top 200,000 bins per histone
mark and individual were kept. These top-ranked bins were further
filtered such that only those that were present in at least three in-
dividuals for either mark were kept. For mapping promoters with
the H3K4me3 mark, only bins mapping within 1 kb of the TSS
of known RefSeq transcripts were considered. Finally, enhancers
were identified with the H3K4me1 mark under the condition
that no H3K4me3 bins could overlap.
Whole-Genome Bisulphite Sequencing
Whole genome bisulphite sequencing (WGBS) and library con-
struction were carried out as described by Kulis et al.9 In brief,
1 mg of adipose-tissue-derived DNA was spiked with 0.2% unme-
thylated l DNA (Promega) and sheared by sonication to 150–
300 bp with a Covaris E220 Focused-ultrasonicator. Genomic
DNA libraries were constructed with the TruSeq Sample Prepara-
tion Kit (Illumina) according to Illumina’s standard protocol. After
adaptor ligation, bisulphite conversion was carried out with the
Epitect Fast Bisulphite Kit (QIAGEN) according to the manufac-
turer’s protocol, ensuring conversion efficiency of >99%. The
adaptor-ligated DNA was then enriched through four to eight
cycles of PCR with the KAPA HiFi HotStart DNA Polymerase Kit
(KAPA Biosystems). Library quality and quantity were monitored
with the Agilent 2100 BioAnalyzer (Agilent) and the Quant-iT
PicoGreen dsDNA Assay Kit (Life Technologies).
Each sample was sequenced on one lane of an Illumina HiSeq
2000 or 2500 system with the use of 100 bp paired-end
sequencing, yielding on average 366 million total reads per sam-
ple. Reads were aligned to the bisulphite-converted reference
genome with the Burrows-Wheeler Aligner; (1) clonal reads, (2)
reads with a low-mapping quality score (<20), (3) reads with a
more than 2%mismatch to the converted reference over the align-
ment length, (4) reads mapping to the forward and reverse strand
of the bisulphite-converted genome, (5) read pairs not mapped to
the expected distance according to the library insert size, and (6)
read pairs mapping in the wrong direction were removed as
described by Johnson et al.39 For avoiding potential biases in
downstream analyses, the followingWGBS-interrogated CpG sites
were further filtered: sites not covered by at least three reads, sites
overlapping a SNP (dbSNP 137), and sites overlapping DAC Black-
listed Regions or Duke Excluded Regions generated for the
ENCODE project. The mean genome coverage was estimated to
be ~7-fold.Journal of Human Genetics 93, 876–890, November 7, 2013 879
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Figure 1. Distribution of Assessed Methylation Sites Based on
Genomic Regions
Methylation sites were categorized in groups on the basis of their
genomic location (x axis). The promoter region includes methyl-
ation sites located in a window of 1,500 bp upstream of the TSS,
in the 50 UTR, and in the first exon. Intergenic regions include
methylation sites not mapping to any of the other categories,
and ambiguous sites refer to sites that fell in at least two different
categories. ‘‘TVSs’’ stands for top 10% of variable sites, and ‘‘All’’
stands for all mapped methylation sites (n ¼ 344,303).Results
Adipose DNA Methylation Profiles in Twins
DNA methylation profiles were successfully obtained from
subcutaneous abdominal adipose tissue from 648 female
twins (97 MZ pairs, 162 DZ pairs, and 130 singletons)
included in the MuTHER study with the use of the Illu-
mina HumanMethylation450 BeadChip. This array har-
bors a total of 485,764 probes, which interrogate almost
exclusively CpG sites (see Subjects and Methods)40. We
restricted our analyses to 344,303 probes (Table S1) that
were unambiguously mapped, did not overlap with any
common sequence polymorphisms, and were successfully
measured in all samples (see Subjects and Methods). These
are referred to here as methylation sites. These methyl-
ation sites were densely distributed across the genome;
the median distance between adjacent sites was 391 bp,
and a large proportion (32.3%) mapped to promoter
regions, defined here as mapping in a window of
1,500 bp upstream of the TSS, in the 50 UTR, or in the first
exon of RefSeq transcripts. Of the 23,667 RefSeq genes,
20,144 (85.1%) had at least one site, and the average was
17 methylation sites per gene. We estimated 65,821
(19.1%) sites to be located in CGIs, where CpGs are highly
clustered and mostly located near gene promoters and
expressed genes; the mean methylation level was beta ¼
0.15 (Figure S3). This observation in adipose tissue is in
line with previous findings showing hypomethylation of
CGIs in other cell types.41
We then compared methylation levels of the 344,303
sites across all individuals and noted little variation at
most sites (Figure S4). When restricting to the top 10% of
variable sites (TVSs), we found enrichment in gene bodies
(p ¼ 1.7 3 104) and intergenic regions (p < 1 3 105),880 The American Journal of Human Genetics 93, 876–890, Novembwhereas promoter regions were depleted of TVSs (p <
1 3 105) (Figure 1). Similarly, we found TVSs to be
depleted in CGIs (Figure S5).
As previously shown, methylation levels of nearby CpG
sites tend to be correlated.18,22 We found approximately a
third of the TVSs to be clustered with a maximum probe-
pair distance of 1 kb. The correlation of methylation levels
between probes decreased with increasing interprobe
distance (rho1–100 bp ¼ 0.75 versus rho900–1,000 bp ¼ 0.25)
and dropped significantly once it exceeded 300 bp. Given
that most of the non-TVSs exhibited minor variation
across individuals, it is not a surprise that the correlation
pattern of adjacent probes differed from that of TVSs
(Figure S6).
DNA Methylation Variation and the Impact of Gene
Expression
The MuTHER adipose tissue samples included here have
previously been profiled on the IlluminaHT12 array for
global gene expression patterns.10 Therefore, we were
able to study the degree of association between DNA
methylation and expression of nearby genes in this
tissue. We limited the analysis to methylation sites that
directly mapped to a RefSeq gene or 1,500 bp upstream
of the TSS (see Subjects and Methods). Because the major-
ity of genes harbor multiple methylation sites and ex-
pression probes, we ended up with 210,984 methylation
and 18,818 expression probes situated in 13,532 genes.
For any given gene, we tested associations between all
methylation and expression-probe combinations map-
ping to the same transcript. From 314,697 associations,
we found 7,706 to be significant at a 1% FDR (p ¼
2.6 3 104) (Table S2), indicating that 6,933 methyla-
tion sites (3.2% of the tested sites) and 2,334 genes
(17.2% of the tested genes) had at least one significant
association. Extending the support for earlier find-
ings18,42 with regard to the direction of the effect, we
found only a slight enrichment of negative correlations
(median beta ¼ 0.015) among all significant associations
between DNA methylation and gene expression (Fig-
ure 2A), indicating that a large proportion of the signifi-
cant associations were positive, i.e., increased methylation
was linked to increased expression of the corresponding
gene. We further divided our methylation-expression
correlations into three groups based on the location(s)
of the methylated site (promoter region, gene-body re-
gion, and 30 UTR) and found negative correlations in all
of them; median beta in promoter regions, gene-body
regions, and 30 UTRs was 0.018, 0.013, and 0.007,
respectively. However, when we restricted to TVSs, we
observed negative correlations for the sites located in
promoter regions (median beta ¼ 0.03) and positive cor-
relations for those closer to 30 UTRs (median beta ¼ 0.02)
(Figure 2B). This paradox of the positive correlation be-
tween gene-body methylation and gene expression levels
is in line with previous reports43,44 but remains largely
unexplained. However, it was recently suggested thater 7, 2013
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Figure 2. DNA Methylation Variation and the Impact of Gene
Expression
We studied the correlation between DNAmethylation and expres-
sion variation in adipose tissue by associating methylation sites
mapping to RefSeq genes or 1,500 bp upstream of the TSS with
the corresponding transcripts from the IlluminaHT12 expression
array.
(A) Histogram showing the direction of effect (x axis) of all 7,706
associations significant at a 1% FDR; the vertical red line high-
lights the median value.
(B) Box plot of the direction of effect (x axis) of the significant
associations limited to TVSs categorized in groups based on the
location(s) of the methylation site (y axis). The five-number
summaries in the plot of each group represent the smallest obser-
vation, lower quartile, median, upper quartile, and largest observa-
tion (sample maximum). The vertical red line indicates the central
point of 0.gene-body methylation might serve to repress spurious
transcription from intragenic promoters and thus allow
for more efficient transcriptional elongation.45The AmericanImpact of Genetic and Environmental Factors on DNA
Methylation
Because our study included MZ (n ¼ 97) and DZ (n ¼ 162)
twin pairs, we were able to distinguish between genetic
and environmental effects on methylation variation and
estimate their respective contributions. We first sought to
study the correlation of adipose methylation states be-
tween individuals sharing 100% (MZ) or 50% (DZ) of the
genetic makeup, as well as between unrelated individuals.
Both using all sites and limiting to TVSs, we noted that
concordance in methylation between MZ twins was
greater than that in DZ twins and unrelated individuals,
indicating genetic influences of DNA methylation
(Figure S7). Given the invariability of methylation levels
for the majority of the sites, correlation levels were rela-
tively higher in the analysis of all sites (Figure S7A) than
in that of only TVSs (Figure S7B). Next, we estimated
narrow-sense heritability, h2, for 344,092 methylation sites
by using a variance-component model adjusting for
the identified technical cofactors (see Subjects and
Methods).30 The average h2 estimates of methylation sites
genome-wide corresponded to 0.19, which is well in agree-
ment with estimates from a smaller twin study11 using the
Illumina HumanMethylation27 panel. However, this array
targets only sites located within proximal promoters of
known genes (~27,000 CpG sites in total). Here, we noted
that the heritability estimate was considerably increased
when we took variance into account (Figure S8). Limiting
to the TVSs, we estimated that, on average, as much as
37% (median h2 ¼ 0.34) of the phenotypic variance can
be in fact attributed to genetic factors (Figure 3A).
As was the case for TVSs, we noted that highly heritable
sites (h2 > 0.5, n ¼ 48,072) were depleted in promoter
regions (p < 1 3 105), which are known to be mainly
hypomethylated.45 As such, when we compared the
methylation profiles of these highly heritable sites to those
of nonheritable sites, we found an enrichment of hyper-
methylation among highly heritable sites (Figures S9A
and S9B). In addition, we also found that the proportion
of heritable methylation sites was associated with genomic
locations, given that significantly more heritable sites were
noted in gene-body or intergenic regions than in regions
close to the TSS (p < 1 3 105) (Figure S9B).
Twin studies also allow calculation of the proportion of
phenotypic variation attributable to familial nongenetic
factors, i.e., the shared common environment. We found
shared environment to contribute little to methylation
variation in adipose tissue (i.e., average 2% of TVSs and
0.2% of all sites), indicating that the remaining proportion
of the nongenetic variance was due to nonshared environ-
ment and stochastic factors (Figure 3B). However, for 8,638
sites, we found shared environmental effect to account for
more than 30% of the total variance in methylation levels.
These sites, corresponding to 4,133 unique genes, were
subjected to pathway analysis, where we found them to
be significantly associated with functions related to meta-
bolic diseases (p ¼ 2.5 3 1010). The top five functionsJournal of Human Genetics 93, 876–890, November 7, 2013 881
Table 1. Top Functions of Genes with CpG Sites Affected by
Shared Common Environment
Category Function Annotation p Value
Number
of Genes
Metabolic disease glucose-metabolism
disorder
2.47 3 1010 193
Metabolic disease diabetes mellitus 1.41 3 109 176
Metabolic disease insulin resistance 1.80 3 108 106
Metabolic disease non-insulin-dependent
diabetes mellitus
4.79 3 108 88
Metabolic disease insulin-dependent
diabetes mellitus
3.55 3 104 70
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Figure 3. Genetic and Nongenetic Effect on Adipose DNA
Methylation
For adipose methylation levels of TVSs (n ¼ 34,430; measured on
the Illumina450K array), the proportion of variation attributable
to (A) genetic (h2) or (B) familial nongenetic factors (shared
common environment [CE]) was estimated. The y axis shows
the proportion of CpG sites at the h2 or CE cutoff indicated on
the x axis. The dotted line represents median estimates.associated with these genes are listed in Table 1 and
include functions related to diabetes mellitus. Interest-
ingly, when associating methylation levels of our TVSs
with concurrently measured insulin levels, we noted a
2.3-fold enrichment (p < 1 3 105) of insulin-associated
methylation sites regulated by shared environment fac-
tors among all significant associations (Bonferroni p <
1.4 3 106).
Common Variants Regulating DNA Methylation in
Adipose Tissue
Tomap the underlying (common) genetic effect of adipose
DNA methylation levels, we performed metQTL mapping
by associating methylation levels with common sequence
variants (MAF > 0.05) located close to the methylation site
(CpG site 5 100 kb). This was performed with imputed
HapMap2 genotypes in a linear mixed (polygenic) model
and a subsequent score test accounting for relatedness.
We called metQTL at a 1% FDR, corresponding to p <
8.6 3 104, and detected a high number of associations,
i.e., 98,085 (28.5%) of the sites tested (corresponding to
74,174 unique SNPs) had a significant association with a
common sequence variant (Table S3). The sequence vari-
ants associated with the methylation traits were overrepre-882 The American Journal of Human Genetics 93, 876–890, Novembsented in regions close to the methylation site (Figure 4).
Applying a more conservative threshold for significance
as the Bonferroni correction (p < 1.2 3 109) led to the
detection of 36,139 (10.5%) sites with a significant associ-
ation. Although extensive filtering of probes was done
prior to analysis (see Subjects and Methods) on the basis
of known sequence variants both within the probe and
at the CpG site, we did not rule out the possibility of addi-
tional low-frequency or rare variants at the CpG site, ex-
plaining some of these associations.
For the sites associated with at least one common
sequence variant at a 1% FDR, the average h2 estimate
was 0.32, and when we restricted to those passing the Bon-
ferroni correction, h2 was markedly higher (h2 ¼ 0.44). We
then sought to estimate how much of the heritability of
eachmethylation site was driven by the identified metQTL
SNPs. Because the current sample size was not sufficient for
obtaining reliable h2 estimates of less than 0.1, we focused
on the TVSs with h2 > 0.1 (n ¼ 21,144) and combined the
results from the heritability and metQTL analyses. We
found that 15% of the sequence variants each explained
more than 50% of the methylation heritability per site
and that, on average, common variants explained 19%
of the total genetic variance of DNA methylation
(Figure S10). Taken together, the genetic contribution of
the variation in methylation for a large proportion of the
measured sites seems to be linked to a limited number of
common variants.
In an attempt to study shared genetic regulation and
links between DNA methylation and gene expression in
adipose tissue, we overlapped our metQTL with eQTL
from the same tissue and sample set.10 Of the 3,478 adi-
pose tissue eQTL mapping to 3,142 genes at a 1% FDR,
we found that 751 (21.6%) of the eQTL overlapped with
at least one metQTL (i.e., a total of 1,510 metQTL overlap-
ped with the 751 eQTL) at a similar significance (1% FDR)
and also when LDwas taken into account (see Subjects and
Methods), i.e., sequence variants at 751 loci regulated both
expression and DNA methylation of the corresponding
gene (Table S4). These 751 loci corresponded to 702 genes
(22.3%). We then studied whether there was a direct asso-
ciation between DNA methylation and gene expression at
these 751 loci (Table S2). We found that 223 of the 751 locier 7, 2013
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Figure 4. Distribution of Top SNPs Associated with the Probe
We performed metQTL analysis by associating methylation levels
with common sequence variants (MAF> 0.05) located close to the
probe (probe 5 100 kb). The histogram shows the distance from
the methylation site (kb, x axis) for the significant associations
identified at a 1% FDR.also had a significant association (1% FDR) between gene
expression and DNA methylation and were enriched
with negative correlations (median beta ¼ 0.02). These
223 eQTL were linked to 444 unique metQTL (a total of
473 metQTL), which we thereafter considered our set of
high-confidence expression metQTL (Table S5).
Degree of Tissue Dependency of Expression metQTL
We next sought to study tissue dependency and indepen-
dency of the 444 expression metQTL (i.e., genetic variants
regulating both gene expression and DNA methylation in
adipose tissue) and thus included data from eQTLmapping
efforts in multiple tissues,10 such as skin and lymphoblas-
toid cell lines (LCLs). As described above, these 444 loci
corresponded to 223 unique eQTL or genes, indicating
that multiple methylation sites regulated by the same
variant overlap with the same eQTL. Interestingly, when
assessing tissue independency by studying shared effects
at a 1% FDR, we found 58% of these adipose eQTL to be
significant in at least one other tissue at a similar FDR.
Using a conservative threshold of calling tissue-dependent
effects (p > 0.05 in both LCLs and skin), we found that
20% of the eQTL were, however, restricted to adipose tis-
sue. Thus, only a small proportion of expression metQTL
appeared to be restricted to gene regulation in adipose tis-
sue, although confirming this pattern will require the
assessment of additional tissue types.
Given the high abundance of adipose metQTL, we next
aimed to study the tissue dependency by performing repli-
cation studies in a subset of the samples where peripheral-
blood-derived DNAwas collected for methylation profiling
with the Illumina450 array (n ¼ 200). Of the 98,085 adi-
pose tissue metQTL identified at a 1% FDR, 88,751 were
available for testing in the corresponding blood-sample
set. We found that 31,735 (35.7%) of the adipose tissue
metQTL replicated in whole blood (same direction, p <
0.05) (Table S6). Estimating the proportion of true positivesThe Americanfrom the enrichment of low association p values (see Sub-
jects and Methods), we confirmed the high replication rate
of metQTL as p1 ¼ 0.49 (Figure S10). The replication rate
was significantly increased (p ¼ 2.3 3 1016) when we
restricted to either TVSs, Bonferroni-corrected metQTL,
or metQTL overlapping eQTL; as much as 48% of the
TVS metQTL, 52% of the Bonferroni-corrected metQTL,
and 52% of the expression metQTL were replicated in
whole blood. The difference in replication rate might
have been due to larger effect sizes of individual metQTL
among the TVSs or enrichment of tissue-dependent
metQTL with smaller effect sizes among all sites where
the replication cohort lacked sufficient power to detect
those effects. The correlation between highly heritable
sites and significant replicated and nonreplicated metQTL
is shown in Figure S12.
Epigenetic-Variant Annotation Using Regulatory-
Element Mapping
As discussed above, we found that population variability of
individual methylation sites was depleted in promoter re-
gions (Figure 1).We also showed thatmost variablemethyl-
ation sites led to no detectable changes in gene expression.
Together, these findings indicate that methylation varia-
tion has ‘‘structure’’ and that blind mining of variable sites
across the genome is likely to be ineffective in building
insight into disease biology given the considerable
nonfunctional methylation pattern. As a first hypothesis-
free approach to understanding where the epigenetic
variants lie in our 450K population data, we used publicly
available reference epigenome data on human cells differ-
entiated into adipocytes from the NIH RoadMap Epige-
nomicsMapping Consortium.23 The NIH RoadMap Project
has not developed full integrative epigenomes from these
cells, but chromatin mark data have been generated
in five independent samples. We considered marks in-
formative for active promoter (H3K4me3)46,47 and en-
hancer (H3K4me1) function48 and employed a simple
background-subtracted binning approach.38 Considering
only autosomes, we divided each data set into 100 bp
bins, and after background subtraction and normalization,
we restricted the analysis to the top200,000bins per sample
(see Subjects and Methods). We then picked the bins pre-
sent in at least three of the five samples for either mark.
ForH3K4me3, we further restricted to binsmappingwithin
1 kb of the TSS of known RefSeq transcripts. Finally,
H3K4me1 bins overlapping with H3K4me3 were excluded.
These binswere thenoverlappedwithourmethylation sites
from the 450K data, which showed that 10,180 of 344,303
(3%) methylation sites were uniquely annotated to
enhancer elements and 72,983 of 344,303 (21%) CpG sites
were uniquely annotated to promoter elements (Table S7).
These annotated regions, particularly promoter regions,
were shown to be less variable than nonannotated regions
(median varenhancer ¼ 7.9 3 104, median varpromoter ¼
9.5 3 105, median varnonannotated ¼ 6.1 3 104), as
well as have distinct methylation profiles with clearJournal of Human Genetics 93, 876–890, November 7, 2013 883
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Figure 5. Annotation of Functional Epigenetic Variation in Regulatory Elements
(A–C) DNA methylation sites assessed by the Illumina 450K array were correlated with regulatory elements in human adipocytes from
the NIH RoadMap Epigenomics Project with the use of the H3K4me1 (enhancer) and H3K4me3 (promoter) marks. Methylation profiles
(beta-values, x axis) of methylation sites overlapping (A) distal regulatory elements (enhancers, n ¼ 10,180), (B) promoter elements (n ¼
72,983), and (C) nonannotating regions (n ¼ 261,140) are plotted.
(D) Bar plot showing the proportion (%, y axis) of all methylation sites (blue bars, n ¼ 344,303), metQTL (orange bars, n ¼ 98,085),
metQTL overlapping with eQTL independently of tissue type (red bars, n ¼ 360), metQTL overlapping with eQTL in adipose tissue
only (green bars, n ¼ 70), metQTL overlapping disease loci (purple bars, n ¼ 3,583), and metQTL overlapping metabolic disease loci
(light blue bars, n ¼ 383) in enhancer (left) and promoter regions (right). *p < 0.05, **p < 104, Fisher’s exact test.hypomethylated states in the annotated regulatory regions
(Figure 5). We then sought to correlate our epigenetic vari-
ants with their genomic location. For this purpose, we first
used the metQTL shown to overlap with an eQTL in the
same tissue as described above (n ¼ 444) and divided this
set of expression metQTL into those that were restricted
to adipose tissue alone (20%) and the remaining expression
metQTL. For both sets of sites, we noted significant enrich-
ment (p < 13 105) in proximal regulatory elements (pro-
moters) compared to all metQTLs (Figure 5D), which was
most likely due to the fact that eQTL themselves were en-884 The American Journal of Human Genetics 93, 876–890, Novembriched in these regions. However, for the expression
metQTL restricted to adipose tissue, we also noted signifi-
cant enrichment (p ¼ 0.03) in distal regulatory (enhancer)
elements (Figure 5D), which is well in line with the
notion that enhancer elements are involved in tissue-spe-
cific gene regulation. Next, we examined metQTL that
overlapped with disease or trait loci reported in the
National HumanGenome Research Institute GWAS catalog
(accessed January 2, 2013). Of the 74,174 sequence variants
associatedwith at least onemethylation site (metSNPs) (see
above) and their proxies (R0>0.8), 2,768overlappedwith ater 7, 2013
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Figure 6. Example Region of a metQTL Overlapping with a BMI Locus Mapping to an Enhancer Element in Adipose Tissue
(A) The methylation site measured by the cg01884057 probe (red panel) mapped to an enhancer bin region (chr2: 25,149,200–
25,150,300) identified in four independent adipocyte samples included in the NIH Roadmap Epigenomics Project (blue panel). The
methylation site (cg01884057, red panel) was significantly associated (p ¼ 1.5 3 1014) with the nearby rs713586 SNP (green panel),
which is also a GWAS locus for BMI. The rs713586 SNP was in perfect LD (R0 ¼ 1) with rs6749422 (black panel), recently identified
in the 1000 Genomes Project.
(B) Methylation profile of the cg01884057 methylation site; the beta-value (x axis) indicates the hypomethylated state.
(C) A scatterplot of the association between rs713586 genotypes (x axis) and cg01884057methylation (y axis) is represented by residuals
from the metQTL model after adjustment for confounders.least one disease locus and were included here for func-
tional annotation. As we did for the expression metQTL,
we divided the set of sites into those that overlapped with
a metabolic disease locus (Table S8) and the remaining
disease or trait loci. Interestingly, for both sets we noted sig-
nificant enrichment (p < 0.0001) of metSNPs associated
with a disease locus in distal (enhancer) regulatory ele-
ments but that metQTL overlapping metabolic trait loci
had a slightly more pronounced effect (1.9-fold versus
1.7-fold) (Figure 5D). As proof of principle, we followed
up in more detail with one of the top metabolic disease
loci overlapping an enhancer metQTL, namely the SNP
rs713586, which is associated with body mass index
(BMI) from a large GWAS of almost 250,000 individuals49
and is a metQTL for the nearby cg01884057 site (chr2:
25,150,051) (Figures 6A–6C). The enhancer regionmapped
to chr2: 25,149,200–25,150,300 and included three addi-
tional CpG sites measured by the 450K array: cg08526959
(chr2: 25,149,334), cg22480783 (chr2: 25,149,622), and
cg15423357 (chr2: 25,149,977) (Figure 7). Apart from
cg01884057 (p ¼ 1.49 3 1014), only cg15423357 (p ¼
3.3 3 1011) was associated with the rs713586 SNP, and
both had low methylation levels. We next sought to fine
map and validate the methylation status and sequence-
dependent effect and thus performed WGBS experiments
in 30 adipose samples (Figure 7). In total, 41 methylation
sites in the enhancer region were measured by WGBS,
and the methylation levels of the four sites corresponding
to the 450K probes were significantly correlated (Spearman
rho ¼ 0.99). Because of our limited sample size for WGBS,
we restricted the replication of the sequence-dependentThe Americaneffect to the hypomethylated region showing an associa-
tion with rs713586 on the 450K array, i.e., chr2:
25,149,628–25,150,147. Our WGBS covered 23 CpG sites
in this region; however, only 9 of the 23 sites had measure-
ments from at least three individuals per rs713586-geno-
type group and were included in the replication analysis.
The overall direction of effect was in agreement with the
450K data, and a combined test of all CpG sites confirmed
the significant rs713586-genotype dependency of methyl-
ation status in the region (Spearman rho ¼ 0.21, p ¼
2.03103) (Figure 7). Interestingly, rs713586was inperfect
LD (i.e., LD ¼ 1) with an untyped 1000 Genomes SNP
(rs6749422, chr2: 25,150,011) that maps to the refined
enhancer region just downstream of our top methylation
association (Figure 7). More specifically, as shown by
RegulomeDB,50 rs6749422 directly overlaps with four tran-
scription factor binding sites identified by the ENCODE
project;51 these include USF1, previously linked to tran-
scriptional control of metabolic processes and metabolic
disorders.46,47 This is of interest because the refined
enhancer region is <10 kb upstream of ADCY3, which en-
codes a protein that belongs to the adenylate cyclase family
of enzymes responsible for the synthesis of cyclic AMP and
has been linked to obesity (MIM 601665)52 and metabolic
processes such as the insulin-signaling pathway53.Discussion
We performed a large population-based methylation sur-
vey of >450,000 CpG sites across the genome in 648Journal of Human Genetics 93, 876–890, November 7, 2013 885
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Figure 7. Validation of Disease-Linked
Enhancer Region by WGBS
(A) The methylation status (y axis) of
methylation sites in the complete enhancer
region (chr2: 25,149,200–25,150,300) was
measured by the Illumina450K array (red
bars) or WGBS (blue bars). The black arrow
indicates the top methylation site associ-
ated with the rs713586 SNP.
(B) WGBS replication analysis of the
methylation status (y axis) of nine methyl-
ation sites and rs713586 genotypes (x
axis). The black arrow indicates the top
CpG site associated with the rs713586
SNP on the Illumina450K array.deeply phenotyped female twins from the MuTHER adi-
pose tissue resource by using the Illumina 450K array. In
this study, we integrated our methylation data with exist-
ing genetic and gene expression information,10 extending
our understanding of the regulation of global DNAmethyl-
ation patterns and the degree of interindividual variation.
For instance, we showed that there is remarkably low vari-
ance in globalmethylation patterns across healthy individ-
uals after technical and biological factors such as age are
taken into account.11 This invariability in methylation
levels has an impact on the discovery rate of the various
analyses performed and has a pronounced effect on global
heritability estimates and detected metQTL (Figure S13).
We also note that population variability in DNA methyl-
ation is suppressed in regions known to be important in
gene regulation, such as promoters, whereas variable
methylation sites are found in gene-body and intergenic
regions. These findings are in line with evidence showing
that epigenetic states at promoter regions are evolution-
arily conserved,54 and such regions are believed to have
low levels of variation. In parallel, we confirmed the in-
verse relationship of methylation states in promoter versus
gene-body regions in that CpG sites around the TSS were
shown to be hypomethylated, whereas clear hypermethy-
lation was seen for sites located in gene bodies.55 The dense
coverage of CpG sites across most RefSeq genes22 allowed a
comprehensive assessment of directionality for associa-
tions between DNA methylation and gene expression.886 The American Journal of Human Genetics 93, 876–890, November 7, 2013First, we confirmed previous studies
showing only a slight enrichment
of negative correlations between
DNA methylation and gene expres-
sion.18,42 Second, when taking CpG
site variability into account, we found
evidence that the direction of the
effect of DNA methylation on the
expression of neighboring genes is
dependent on the genomic location
of the CpG site. As expected, signifi-
cant associations between promoter
DNA methylation and gene expres-
sion were found to be negative, butthere were indications of the opposite scenario (i.e., posi-
tive correlations) for associations between gene-body
(including the 30 UTR) DNA methylation and gene ex-
pression.43,44 This phenomenon has been suggested to
be related to elongation efficiency and prevention of
spurious initiation of transcription.45 Namely, a high level
of gene-body methylation might improve transcription
efficiency of actively transcribed genes by interfering
with nonproductive transcription initiation within tran-
scribed regions.44
With the advantage of a twin-study design, we were also
able to perform large-scale heritability analysis of DNA
methylation patterns not limited to promoter CpG sites,
as were previous studies.11,56 These nonpromoter (gene-
body and intergenic), hypermethylated CpGs were found
not only to be highly variable across individuals but also
to be regulated to a large extent by genetic factors. This
pattern was further supported by metQTL mapping
showing a high degree of sequence dependency of variable
CpG sites. However, the majority of these genetically
controlled CpG sites seem to be ‘‘neutral’’ without a clear
biological or functional mechanism such as changes in
gene expression or disease risk. This is, in fact, in agree-
ment with a recent report in which the mouse methylome
showed a high degree of sequence dependency of methyl-
ation sites occurring at bases adjacent to the CG site57 and
might indicate high sequence specificity for the DNA
methylation machinery even in the human methylome.
Nevertheless, we show examples of how functional epige-
netic variants important in gene regulation or disease
susceptibility can be identified and characterized by the
integration of methylome data with reference epigenomes.
Using ChiP-seq data from human cells differentiated into
adipocytes (from the NIH RoadMap Epigenomics Mapping
Consortium),23 we found that metQTL overlapping eQTL
restricted to adipose tissue or metabolic-trait or disease
loci were enriched in distal regulatory elements (i.e.,
enhancers). These enhancer elements were mostly hypo-
methylated, which is in line with previous findings of
the correlation between low methylation levels and open
chromatin.18,58 This is believed to occur to facilitate
chromatin accessibility for the cellular machinery and
thereby modulate the transcriptional potential of the un-
derlying DNA sequence.59 These findings also highlight
the tissue- or cell-specific nature of disease-associated
gene regulation and that, similar to transcriptomic ap-
proaches designed for understanding disease associations
and their underlying biological mechanisms, epigenomic
studies require samples that are directly targeted to the
disease or trait of interest. Our findings also support
recent reports of the enrichment of disease SNPs in active
chromatin measured by DNaseI hypersensitivity sites60 or
within enhancer elements specifically active in relevant
cell types,61 but our data indicate that this association is
due to genetically driven methylation variation occurring
at these regulatory elements. Using WGBS, we followed
up with one of the metabolic disease and adipose-tissue-
specific metQTL identified in our adipose 450K array anal-
ysis. The association mapped to an enhancer element
located ~10 kb upstream of ADCY3, which has been linked
to multiple metabolic diseases and processes.52,53 Our fine-
mapping efforts here suggest that the link between the
enhancer metQTL and the regulation of the metabolic-
disease-associated gene is through altered binding of a
transcription factor. This as the sequence variant (associ-
ated with adipose DNA methylation status and BMI from
large GWASs) seems to alter the binding of USF1, which
is known to be a transcription factor controlling the
expression of several genes involved in lipid and glucose
homeostasis.
In conclusion, we present a unique large-scale popula-
tion- and tissue-based methylome survey by the Illumi-
na450K array. Our results showed low levels of variation
in global CpG methylation, particularly in hypomethy-
lated promoter regions, which still represent a substantial
proportion of sites included on the 450K array. On the
other hand, gene-body methylation and intergenic CpG
methylation showed a different pattern: apart from being
more hypermethylated, they were also more variable
across individuals with a higher degree of heritable
sequence dependency. The exact biological role of this
phenomenon remains unclear and warrants continued
investigation. Finally, we show evidence that the presence
of functional relevant hypomethylated regions mapping
to regulatory elements specific to adipose tissue plays aThe Americankey role in adipose-dependent gene regulation and meta-
bolic-disease susceptibility. These regions are, however,
only sparsely covered by the 450K array, and together
with the small fraction of methylation variation accessible
through this targeted array, our data highlight the need for
more comprehensive and unbiased disease-tailored studies
of CpG variation in the future.Supplemental Data
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